Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10 GBX | -13.04% | -13.04% | -4.76% |
Apr. 17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
Apr. 17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Business Summary
Number of employees: 17
Managers
Managers | Title | Age | Since |
---|---|---|---|
Tiffany Thorn
FOU | Founder | 37 | 15-12-31 |
Adrian Howd
DFI | Director of Finance/CFO | 52 | 23-10-02 |
Simon Wallwork
SEC | Corporate Secretary | - | 21-06-21 |
Oliver Schon
PRN | Corporate Officer/Principal | - | 21-09-13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Kauffman
CHM | Chairman | 60 | 22-01-15 |
William Paris
BRD | Director/Board Member | 73 | 21-09-21 |
Susan Lowther
BRD | Director/Board Member | 65 | 21-09-21 |
Tiffany Thorn
FOU | Founder | 37 | 15-12-31 |
Robert Hawkins
BRD | Director/Board Member | 69 | 21-09-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 82,526,088 | 52,278,670 ( 63.35 %) | 0 | 63.35 % |
Company contact information
BiVictriX Therapeutics Plc
Mereside Alderley Park Alderley Edge
SK10 4TG, Macclesfield
+
http://www.bivictrix.comSector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.76% | 12.06M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- BVX Stock
- Company BiVictriX Therapeutics Plc